Company: SXTPW
Filing Date: 2025-02-06
Form Type: 424B5
Source: 0001213900-25-010772
Chunk: 42

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-06
Form: 424B5
Chunk 42
---
 shares of Common Stock or Common Stock equivalents, or file any registration statement or any amendment or supplement thereto, other than a prospectus supplement for the registration statement of which this prospectus supplement forms a part. In addition, from the date of this prospectus supplement until one (1) year after the closing of this offering, we are prohibited from effecting or entering into an agreement to effect any issuance of Common Stock or Common Stock equivalents involving a variable rate transaction, subject to certain exception.

Certain Relationships

The Placement Agent and its affiliates have and
may in the future provide, from time to time, investment banking and financial advisory services to us in the ordinary course of business,
for which they may receive customary fees and commissions. The Placement Agent acted as our placement agent in connection with the private
placement we consummated in September 2024 and the January 2025 Offering, for which it received compensation. However, except as disclosed
in this prospectus, we have no present arrangements with Wainwright for any further services.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Equity Stock Transfer, LLCwhose address is 237 West 37th Street, Suite 602, New York, NY 10018 and telephone number is (212) 575-5757

Listing

Our common stock is listed on The Nasdaq Capital Market under the symbol
“SXTP.” On February 4, 2025, the last reported sale price of our common stock on The Nasdaq Capital Market was $0.59.

<div align='center'>S-26

PRIVATE PLACEMENT TRANSACTION</div>

Concurrently with the sale of shares of Common Stock in this offering,
we will issue and sell to the investors in this offering the Private Placement Warrants to purchase up to an aggregate of 1,503,500 shares
of Common Stock at an exercise price equal to $0.59 per share.

The Private Placement Warrants and the shares of Common Stock issuable upon the exercise of such warrants have not been registered under the Securities Act, are not being offered pursuant to this prospectus supplement and the accompanying prospectus, and are instead being offered pursuant to an exemption provided in Section 4(a)(2) under the Securities Act and Rule 506 of Regulation D promulgated thereunder. Accordingly, purchasers may only sell the Private Placement Warrants and the shares of Common Stock issued upon exercise of the Private Placement Warrants pursuant to an effective registration statement under the Securities Act covering the resale of